Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    November 2025
  1. WOO SH, Lee YH, Jung BC, Kim YS, et al
    Pulsed Electromagnetic Field Promotes Doxorubicin-induced Apoptosis by Increasing Caspase-2 Activation in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2025;45:4921-4931.
    PubMed     Abstract available


  2. YANG M, Han J, Won H, Chae SW, et al
    Automated Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma Using Deep Learning on Pretreatment Core Needle Biopsy Samples.
    Anticancer Res. 2025;45:5167-5176.
    PubMed     Abstract available


  3. HUNG CC, Wang YC, Liu CH, Lin ML, et al
    Impact of Interleukin-12B Genotypes on Breast Cancer Risk.
    Anticancer Res. 2025;45:4771-4781.
    PubMed     Abstract available


  4. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    An Investigation of Alexithymia Personality Features Versus Outcome: A Prospective 25-year Follow-up Study in Women With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:5085-5094.
    PubMed     Abstract available


    October 2025
  5. INOUE S, Miki M, Mizumoto S, Yamamoto M, et al
    Immunohistochemical Evaluation of Tumor Characteristic Retention in Triple-negative Breast Cancer PDOX Models.
    Anticancer Res. 2025;45:4169-4180.
    PubMed     Abstract available


  6. NAGASHIMA Y, Sasaki K, Nohata K, Chiwaki R, et al
    High Expression of PKCzeta and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2025;45:4357-4372.
    PubMed     Abstract available


    September 2025
  7. AQUINO IG, DE Almeida PC, Rangel-Coelho JP, DE Castro Raucci LMS, et al
    Influence of Caffeic Acid Phenethyl Ester on Osteoblastic Cell Behavior in Coculture With Breast Adenocarcinoma Cells.
    Anticancer Res. 2025;45:3719-3726.
    PubMed     Abstract available


  8. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    Psychological Stress Versus Outcome in Patients With Breast Disease and Breast Cancer: A Prospective 25-year Follow-up Study in Patients With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:3817-3826.
    PubMed     Abstract available


  9. LYRONIS G, Efraimidou E, Zachou ME, Kaprana A, et al
    Impact of Fentanyl and Remifentanil on Immune Response in Breast Cancer Patients Post-surgery.
    Anticancer Res. 2025;45:3761-3771.
    PubMed     Abstract available


  10. WAGNER JK, Leinhos F, Kunze CA, Bick U, et al
    Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
    Anticancer Res. 2025;45:3749-3760.
    PubMed     Abstract available


  11. CIPOLLA C, Gebbia V, DI Stefano V, Messina C, et al
    Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.
    Anticancer Res. 2025;45:4037-4045.
    PubMed     Abstract available


  12. SAWA A, Sato R, Matsuo T, Okazaki M, et al
    Paclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
    Anticancer Res. 2025;45:3827-3833.
    PubMed     Abstract available


    August 2025
  13. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
    Comparison of Comprehensive Genomic Profiling Testing "Ion Torrent Genexus Sequencer" With FoundationOne.
    Anticancer Res. 2025;45:3479-3486.
    PubMed     Abstract available


  14. IIDA K, Iwabuchi E, Miki Y, Hasegawa K, et al
    Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors.
    Anticancer Res. 2025;45:3221-3230.
    PubMed     Abstract available


  15. PARK SH, Yoon DH, Kim J, Park SI, et al
    Deletion of the POLR2J4 Gene in Breast Cancer Cells Promotes Bone Metastatic Tumor Growth.
    Anticancer Res. 2025;45:3263-3273.
    PubMed     Abstract available


    July 2025
  16. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    PubMed     Abstract available


  17. KAMYAN D, Elemam NM, Alkhayyal N, Talaat IM, et al
    Unlocking New Frontiers in Breast Cancer: The Role of the Tumor Microenvironment, Cutting-Edge Therapies, and Immunotherapy.
    Anticancer Res. 2025;45:2729-2747.
    PubMed     Abstract available


    June 2025
  18. IORIO V, Delia P, Solazzo AP, Fazio I, et al
    Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast Cancer.
    Anticancer Res. 2025;45:2539-2550.
    PubMed     Abstract available


  19. KIM HG, Kang SY, Kim KM, Kim JY, et al
    Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.
    Anticancer Res. 2025;45:2575-2586.
    PubMed     Abstract available


  20. HONG SD, Kang MS, Katuwal NB, Ghosh M, et al
    Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model.
    Anticancer Res. 2025;45:2669-2688.
    PubMed     Abstract available


  21. LEE IH, Kim EA, Lee SJ, Kang B, et al
    The Role of EMP2 in Triple-negative Breast Cancer.
    Anticancer Res. 2025;45:2417-2427.
    PubMed     Abstract available


  22. KOKKONEN K, Utriainen M, Penttinen H, Vehmanen L, et al
    Feasibility of an Exercise Training Program Among Patients With Newly Diagnosed Advanced Breast Cancer.
    Anticancer Res. 2025;45:2605-2618.
    PubMed     Abstract available


    May 2025
  23. RADES D, Bartscht T, Rody A, Yu NY, et al
    Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer.
    Anticancer Res. 2025;45:2123-2135.
    PubMed     Abstract available


  24. TAKADA S, Umehara K, Kanae T, Kimura Y, et al
    Prediction of Severe Anemia and Neutropenia Induced by Abemaciclib in Patients With Breast Cancer.
    Anticancer Res. 2025;45:2171-2183.
    PubMed     Abstract available


  25. KIM J, Han Q, Kang BM, Mizuta K, et al
    Combination of Recombinant Methioninase With Rapamycin or Chloroquine Is Synergistic to Highly Inhibit Triple-negative Breast Cancer Cells In Vitro.
    Anticancer Res. 2025;45:1853-1859.
    PubMed     Abstract available


  26. ZWICKER F, Raether LP, Klepper R, Hauswald H, et al
    Long-term Outcomes of Helical Tomotherapy in Lymph Node-positive Breast Cancer Following Breast-conserving Surgery.
    Anticancer Res. 2025;45:2025-2040.
    PubMed     Abstract available


  27. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    The Impact of State-trait Anxiety Inventory (STAI) Self-evaluation versus 25-year Outcome: A Prospective Follow-up Study in Patients With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:2161-2169.
    PubMed     Abstract available


  28. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
    Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
    Anticancer Res. 2025;45:1807-1812.
    PubMed     Abstract available


  29. RADES D, Bartscht T, Rody A, Ballegaard M, et al
    Two Scoring Tools to Estimate the Risk of Taxane-induced Peripheral Sensory Neuropathy (PNP) in Patients Irradiated for Non-metastatic Breast Cancer.
    Anticancer Res. 2025;45:2115-2121.
    PubMed     Abstract available


    April 2025
  30. TAKEYAMA H, Manome Y, Koyama M, Yoshii Y, et al
    Sialic Acid-Fibronectin-negative and Vimentin-positive Breast Cancers Have Poor Prognoses due to Epithelial-Mesenchymal Transition.
    Anticancer Res. 2025;45:1617-1629.
    PubMed     Abstract available


  31. BHALA R, Cando LF, Verma P, Adesoye T, et al
    Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS).
    Anticancer Res. 2025;45:1305-1328.
    PubMed     Abstract available


  32. MIKI M, Inubushi S, Han Q, Inoue S, et al
    Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2025;45:1367-1372.
    PubMed     Abstract available


  33. FUJII T, Nakazawa Y, Aoki M, Tanabe K, et al
    Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.
    Anticancer Res. 2025;45:1707-1712.
    PubMed     Abstract available


    March 2025
  34. DE SARKAR S, Banerjee S, Ismail A, Mavadia A, et al
    Male Breast Cancer: A Single Institutional Clinicopathological Profiling.
    Anticancer Res. 2025;45:1097-1104.
    PubMed     Abstract available


  35. HAQUE W, Verma V, Mangalampalli N, Schwartz MR, et al
    Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.
    Anticancer Res. 2025;45:1055-1061.
    PubMed     Abstract available


  36. PARK HJ, Namkung HR, Jung SB, Choi KT, et al
    Anticancer Potential of Black Ginseng Extract in a Breast Cancer Cell Xenograft Mouse Model.
    Anticancer Res. 2025;45:1047-1054.
    PubMed     Abstract available


    February 2025
  37. GOERDT L, Stefanovic A, Wirtz R, Karic U, et al
    Correlation of HLA-A and HLA-B/C Expression With ESR1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Distant Disease-free Survival.
    Anticancer Res. 2025;45:445-450.
    PubMed     Abstract available


  38. OSHIRO A, Nagahashi M, Togashi Y, Kanaoka H, et al
    Clinical Utility of Sentinel Lymph Node Biopsy Using the Medical Imaging Projection System in Breast Cancer Patients, Including Those Following Neoadjuvant Chemotherapy.
    Anticancer Res. 2025;45:789-796.
    PubMed     Abstract available


  39. YEARBY LA, Kotina M, Ohemeng A, Banjara B, et al
    Noncancerous Exosomes Establish a Growth Promoting Paracrine Effect on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2025;45:419-431.
    PubMed     Abstract available


  40. MORINAGA S, Han Q, Mizuta K, Kang BM, et al
    Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin.
    Anticancer Res. 2025;45:451-455.
    PubMed     Abstract available


  41. SHIN D, Yoo JO, Jeong JH, Han YH, et al
    MiR-5586-5p Suppresses Hypoxia-induced Angiogenesis Through Multiple Targeting of HIF-1alpha, HBEGF and ADAM17 in Breast Cancer.
    Anticancer Res. 2025;45:473-489.
    PubMed     Abstract available


    January 2025
  42. SATO A, Masaka S, Aisaka A, Ishibashi I, et al
    Hederagenin Glycoside Isolated from the Pericarps of Akebia quinata Fruits Induces Apoptotic Cell Death in Breast Cancer Cells.
    Anticancer Res. 2025;45:135-144.
    PubMed     Abstract available


  43. SATO A, Yabuki A, Sato G, Nemoto H, et al
    Garlic (Allium sativum L.) Organosulfur Compounds Inhibit Breast Cancer Cell Proliferation by Decreasing Steroid Sulfatase Levels.
    Anticancer Res. 2025;45:145-152.
    PubMed     Abstract available


  44. COLLERY P, Desmaele D, Harikrishnan A, Veena V, et al
    Impact of Rhenium(I)-Diselenoether Compound on Cell Adhesion, Migration, Invasion Capacities, and MMP-2 Release in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2025;45:73-79.
    PubMed     Abstract available


  45. ZANG M, Zheng J, An X, Li BO, et al
    Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers.
    Anticancer Res. 2025;45:39-53.
    PubMed     Abstract available


    December 2024
  46. SUGANUMA N, Saito N, Yasukawa M, Yamanaka T, et al
    Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines.
    Anticancer Res. 2024;44:5187-5192.
    PubMed     Abstract available


  47. SUGANUMA N, Matsubara Y, Takahashi A, Yamanaka T, et al
    Impact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.
    Anticancer Res. 2024;44:5225-5230.
    PubMed     Abstract available


  48. OZCIVICI E, Mese G
    Comprehensive Analysis of GJB1 in Breast Cancer: Its Implications in Survival and Molecular Mechanisms.
    Anticancer Res. 2024;44:5379-5391.
    PubMed     Abstract available


    November 2024
  49. QUITMEYER B, Emelife C, Klausner H, Gbayisomore O, et al
    Differential Effects of Punicic Acid on Cytotoxicity and Peroxiredoxin Expression in MCF-7 Breast Cancer and MCF-10A Normal Cells.
    Anticancer Res. 2024;44:4751-4759.
    PubMed     Abstract available


  50. GIRO A, Passildas-Jahanmohan J, Kossai M, Bidet Y, et al
    Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study.
    Anticancer Res. 2024;44:4983-4994.
    PubMed     Abstract available


  51. CHANTARAAMPORN J, Pothipan P, Sakulterdkiat T, Khiankaew B, et al
    CD47 and Calreticulin Expression in Breast Cancer Subtypes and Anti-CD47 Inhibitory Effects in Macrophage-mediated Phagocytosis.
    Anticancer Res. 2024;44:4929-4940.
    PubMed     Abstract available


  52. IKEDA T, Honda CK, Kurozumi S, Yokobori T, et al
    Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis.
    Anticancer Res. 2024;44:4877-4883.
    PubMed     Abstract available


  53. GOTO W, Henmi S, Matsuda H, Nakata K, et al
    Predictive Value of Immune Activity Changes in Breast Cancer Patients Treated With Dose-dense Neoadjuvant Chemotherapy: A Retrospective Study.
    Anticancer Res. 2024;44:5123-5129.
    PubMed     Abstract available


  54. SEKI H, Ishiguro Y, Makino A, Yamaguchi K, et al
    Nomogram Predicting Axillary Lymph Node Dissection Omission After Neoadjuvant Chemotherapy for Node-positive Breast Cancer.
    Anticancer Res. 2024;44:5131-5138.
    PubMed     Abstract available


    October 2024
  55. AHMED ZM, Abouegylah M, Khedr GA, Eich HT, et al
    Radiation-induced Esophagitis in Breast Cancer Patients Treated With Supraclavicular Field Irradiation.
    Anticancer Res. 2024;44:4543-4549.
    PubMed     Abstract available


  56. CHU J, DO SI, Kim HS
    Identifying High Recurrence Risk in Breast Carcinoma Patients Through Spatial Transcriptomic Analysis.
    Anticancer Res. 2024;44:4387-4401.
    PubMed     Abstract available


  57. UENAKA N, Sato E, Horimoto Y, Kawai S, et al
    CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
    Anticancer Res. 2024;44:4525-4536.
    PubMed     Abstract available


  58. YE Y, Wang J, Dillard J, Barsky SH, et al
    Tumor Dormancy Within the Lymphovascular Embolus Is Regulated by Multiple Metabolism-signaling Pathways.
    Anticancer Res. 2024;44:4165-4173.
    PubMed     Abstract available


    September 2024
  59. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available


  60. PALUMBO I, Becchetti AG, Perrucci E, Falcinelli L, et al
    Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects.
    Anticancer Res. 2024;44:3965-3971.
    PubMed     Abstract available


  61. YANO T, Ono Y, Yoshimura M, Ono T, et al
    Postoperative Radiotherapy Using VMAT for RNI Including IMN in Breast Cancer: Report of Short-term Follow-up.
    Anticancer Res. 2024;44:4011-4018.
    PubMed     Abstract available


  62. UCHIYAMA M, Shima H, Kutomi G, Kyuno D, et al
    Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.
    Anticancer Res. 2024;44:4039-4047.
    PubMed     Abstract available


  63. LEE H, Cho YA, Kim DG, Son JY, et al
    Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Anticancer Res. 2024;44:3983-3994.
    PubMed     Abstract available


    August 2024
  64. MAIMON O, Nisman B, Broier S, Ben-David I, et al
    The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report.
    Anticancer Res. 2024;44:3543-3550.
    PubMed     Abstract available


  65. LIU M, Koo D, Jiang WG, Ye L, et al
    Oestrogen Represses Noggin Expression by Interfering With BMP/Smad Signalling in ER Positive Breast Cancer.
    Anticancer Res. 2024;44:3355-3364.
    PubMed     Abstract available


  66. SAHA S, Croyal M, Huvelin JM, Nazih H, et al
    4-Cholesten-3-one Modified the Lipidome of MDA-MB-231 Cells and Potentiated the Effect of Docetaxel.
    Anticancer Res. 2024;44:3277-3285.
    PubMed     Abstract available


  67. TANAKA M, Aoki M, Masuda Y, Yoshinaga Y, et al
    Stromal CD73 Expression in Breast Cancer: Subtype-specific Expression and its Prognostic Significance.
    Anticancer Res. 2024;44:3637-3643.
    PubMed     Abstract available


  68. CAROPRESE M, Conson M, Barillaro A, Feoli C, et al
    Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study.
    Anticancer Res. 2024;44:3501-3506.
    PubMed     Abstract available


  69. NA YM, Park SC, Ryu YJ, Cho JS, et al
    Risk Factors for Non-sentinel Lymph Node Metastasis in HR+/HER2- Breast Cancer With cN0.
    Anticancer Res. 2024;44:3493-3500.
    PubMed     Abstract available


  70. MOKBEL K
    Unveiling the Complex Ecosystem of Breast Cancer: Crucial Insights for Patients and Doctors.
    Anticancer Res. 2024;44:3317-3319.
    PubMed     Abstract available


  71. CHUNG Y, Chu J, DO SI, Kim HS, et al
    Spatial Transcriptomic Profiling Reveals Gene Expression Characteristics in Lymph Node-positive Breast Carcinoma.
    Anticancer Res. 2024;44:3381-3395.
    PubMed     Abstract available


    July 2024
  72. WOO SH, Jung BC, Kim JY, Lee YH, et al
    PEMF Potentiates Doxorubicin-induced Late G(2) Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2024;44:2837-2846.
    PubMed     Abstract available


  73. TAO X, Na LI, Hu EX, Wang J, et al
    Clinical Diagnostic Value of circ-ARHGER28 for Breast Cancer and its Effect on MCF 7 Cell Proliferation and Apoptosis.
    Anticancer Res. 2024;44:2877-2886.
    PubMed     Abstract available


  74. HEIDINGER M, Egle D, Piscuoglio S, Navarro-Aguadero MA, et al
    Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast Cancer.
    Anticancer Res. 2024;44:2981-2988.
    PubMed     Abstract available


  75. NIEDER C, Haukland EC, Mannsaker B
    Return to Work After Breast Cancer Treatment: An Electronic Health Record-based Study in North Norway.
    Anticancer Res. 2024;44:3193-3198.
    PubMed     Abstract available


    June 2024
  76. CHU J, DO SI, Kim HS
    Age-related Differences in Spatially Resolved Transcriptomic Profiles of Patients With Hormone Receptor-positive Breast Carcinoma.
    Anticancer Res. 2024;44:2605-2616.
    PubMed     Abstract available


  77. WOO SH, Jung BC, Kim JY, Lee YH, et al
    Pulsed Electromagnetic Field Enhances Caffeic Acid Phenethyl Ester-induced Death of MCF-7 Breast Cancer Cells.
    Anticancer Res. 2024;44:2407-2415.
    PubMed     Abstract available


  78. CHANG CM, Pekkle Lam HY
    Intratumoral Microbiota: Unraveling their Oncogenic Impact on Cancer Progression With Focus on Breast Cancer Therapeutic Outcomes.
    Anticancer Res. 2024;44:2271-2285.
    PubMed     Abstract available


  79. PIOQUINTO-AVILA E, Gonzalez-Cruz AO, Solis-Estrada J, Hernandez-Juarez J, et al
    Anticancer Activity of HER2-targeting CPP-PTEN-THP Chimeric Proteins.
    Anticancer Res. 2024;44:2567-2575.
    PubMed     Abstract available


  80. GUNNELLINI M, Tornincasa A, Montedoro M, Caprodossi A, et al
    Neoadjuvant Treatment for a cT4cN+ HER2+ Breast Cancer: Case Report of a Therapeutic Success.
    Anticancer Res. 2024;44:2755-2758.
    PubMed     Abstract available


  81. MOKBEL K, Mokbel K
    Harnessing Micronutrient Power: Vitamins, Antioxidants and Probiotics in Breast Cancer Prevention.
    Anticancer Res. 2024;44:2287-2295.
    PubMed     Abstract available


  82. SUGAWARA-KOMATSU K, Fujii T, Kurozumi S, Ishikawa H, et al
    Significance of MUC1 and beta-Catenin Localization in Mucinous Carcinoma of the Breast.
    Anticancer Res. 2024;44:2689-2698.
    PubMed     Abstract available


  83. SUWANNALERT P, Panpinyaporn P, Wantanachaisaeng P, Teeppaibul T, et al
    A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization.
    Anticancer Res. 2024;44:2555-2565.
    PubMed     Abstract available


  84. RADES D, Janssen S, Narvaez-Wolf CA, Kristiansen C, et al
    Seasonal Impact on Grade >/=2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis.
    Anticancer Res. 2024;44:2617-2620.
    PubMed     Abstract available


  85. OMORI S, Ijichi H, Wakasugi A, Shigechi T, et al
    Association Between Preoperative Osteopenia and Prognosis in Breast Cancer Patients.
    Anticancer Res. 2024;44:2671-2679.
    PubMed     Abstract available


  86. AGHIMIEN MO, Kolawole Q, Igbinoba PO, Musa MA, et al
    Non-cytotoxic 3-Acetylcoumarin as an Attractive Target for Human Monoamine Oxidase (HMAO) Enzymes.
    Anticancer Res. 2024;44:2335-2341.
    PubMed     Abstract available


    May 2024
  87. VANNI G, Materazzo M, Lorenzo ND, Tacconi F, et al
    Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride in Non-invasive Axillary Staging in Breast Cancer: Are we Missing a Chance?
    Anticancer Res. 2024;44:2021-2030.
    PubMed     Abstract available


  88. GOROBETS O, Keam B, Vinh-Hung V, Nguyen NP, et al
    Twenty-five Years Overall Survival Prognostic Value of the Lymph Node Ratio in De Novo Metastatic Breast Cancer.
    Anticancer Res. 2024;44:1995-2002.
    PubMed     Abstract available


  89. CIPOLLA C, Lupo S, Grassi N, Battaglia MC, et al
    The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
    Anticancer Res. 2024;44:2047-2053.
    PubMed     Abstract available


  90. PERRONE E, Taralli S, Pagliara D, Larocca LM, et al
    Breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After CAR-T Therapy Detected by (18)F-FDG PET/CT.
    Anticancer Res. 2024;44:2243-2245.
    PubMed     Abstract available


  91. PSEFTOGAS A, Xanthopoulos K, Siasiaridis A, Poutahidis T, et al
    Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
    Anticancer Res. 2024;44:1885-1894.
    PubMed     Abstract available


    April 2024
  92. SATO M, Han Q, Mori R, Mizuta K, et al
    Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methion
    Anticancer Res. 2024;44:1499-1504.
    PubMed     Abstract available


  93. CIMPEAN AM, Comsa S, Sturza A, Barb AC, et al
    Validation of Human Bone Marrow-derived Mesenchymal Stem Cells and MCF-7 Breast Cancer Cells Co-culture Using a 3D Perfused Biomimetic Microfluidic Platform.
    Anticancer Res. 2024;44:1441-1453.
    PubMed     Abstract available


  94. KITSUYA N, Matsuoka M, Onodera T, Yokota I, et al
    Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.
    Anticancer Res. 2024;44:1591-1601.
    PubMed     Abstract available


  95. RADES D, Kristiansen C, Timke C, Duma MN, et al
    Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer.
    Anticancer Res. 2024;44:1525-1531.
    PubMed     Abstract available


  96. ARDAVANIS-LOUKERIS G, Kokkali S, Perdikari K, Karatrasoglou E, et al
    A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2024;44:1559-1565.
    PubMed     Abstract available


    March 2024
  97. SHIN JK, Kim HS, Yoon S
    Co-treatment With Aripiprazole and Vincristine Sensitizes P-Glycoprotein-Overexpressing Drug-resistant MCF-7/ADR Breast Cancer Cells.
    Anticancer Res. 2024;44:1051-1062.
    PubMed     Abstract available


  98. JANG SY, Kim J, Hong E, Yang YJ, et al
    Phloretin Inhibits the Proliferation of Breast Cancer Cells Through the Down-regulation of Estrogen Receptor alpha.
    Anticancer Res. 2024;44:1109-1120.
    PubMed     Abstract available


  99. COLLERY P, Prunier C, Dosda E, Viallet J, et al
    Effectiveness of Rhenium(I)-diselenoether Low Doses in a Triple-negative Breast Cancer Chicken Embryo Model.
    Anticancer Res. 2024;44:941-951.
    PubMed     Abstract available


  100. YANG DK, Tungalag T, Lee SJ, Kim SJ, et al
    Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2024;44:1087-1095.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.